Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

@article{Steinberg2007DasatinibAT,
  title={Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.},
  author={Michael L. Steinberg},
  journal={Clinical therapeutics},
  year={2007},
  volume={29 11},
  pages={2289-308}
}
BACKGROUND The Philadelphia chromosome is formed from a translocation of genetic material involving human chromosomes 9 and 22. The resulting gene product, BCR-ABL, encodes for an abnormal tyrosine kinase (TK) that is a factor in the pathology of chronic myelogenous leukemia (CML). Use of targeted therapy that inhibits BCR-ABL kinase activity may lead to hematologic and cytogenetic responses in affected individuals. The oral TK inhibitor dasatinib was approved in 2006 for use in patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

ADME Processes in Pharmaceutical Sciences

Springer International Publishing • 2018

Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 48 references

AIIogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl Kinase mutation-related imatinib failure

E Jabbour, CortesJ, HM Kantarjian
Blood • 2006

Similar Papers

Loading similar papers…